UBS Lux Equity Fund Biotech USD vs Avanza Auto 1

UBS Lux Equity Fund Biotech USD vs Avanza Auto 1

1. UBS Lux Equity Fund Biotech USD

  • Security

    UBS Lux Equity Fund Biotech USD P-acc

  • Fee

    2.25%

  • ISIN

    LU0069152568

  • Holdings

    10

2. Avanza Auto 1

  • Security

    Avanza Auto 1

  • Fee

    0.35%

  • ISIN

    SE0009779655

  • Holdings

    15

Fund Holdings

We have information about 14 holdings in UBS Lux Equity Fund Biotech USD, where the largest holding is Regeneron Pharmaceuticals (10.04), followed by Vertex (9.9) and Moderna (9.21). In comparison with Avanza Auto 1, we have 18 holdings where AMF Räntefond Mix is the largest holding (14.72), followed by Danske Invest Sverige Kort Ränta SA (14.51) and Swedbank Robur Räntefond Kort A (14.5).

All Holdings

Here we compare the holdings in UBS Lux Equity Fund Biotech USD and Avanza Auto 1.

UBS Lux Equity Fund Biotech USD Avanza Auto 1
1. Regeneron Pharmaceuticals Inc
10.04 %
1. AMF Räntefond Mix
Sweden
14.72 %
2. Vertex Pharmaceuticals Inc
9.9 %
2. Danske Invest Sverige Kort Ränta SA
Luxembourg
14.51 %
3. Moderna Inc
9.21 %
3. Swedbank Robur Räntefond Kort A
Sweden
14.5 %
4. Alnylam Pharmaceuticals Inc
6.54 %
4. Amundi Global AGG SRI UCITS I13HSK C
Luxembourg
13.47 %
5. AbbVie Inc
USA
5.52 %
5. Captor Aster Global Credit A
Sweden
8.88 %
6. Gilead Sciences Inc
USA
4.66 %
6. Captor Aster Global Credit Short-Term A
Sweden
8.71 %
7. Amgen Inc
4.32 %
7. Storebrand Global Företagsobligation A SEK
Sweden
4.37 %
8. BioNTech SE
4.13 %
8. Storebrand Global Plus A SEK
Sweden
4.22 %
9. Karuna Therapeutics Inc
3.75 %
9. Avanza Global
Sweden
4.11 %
10. Royalty Pharma Plc
3.28 %
10. Öhman Marknad Global A
Sweden
4.08 %
- 11. Handelsbanken Developed Markets Index Criteria A1 SEK
Sweden
4.07 %
- 12. Avanza Sverige
Sweden
2.01 %
- 13. Handelsbanken Amerika Små Tema A1 SEK
Sweden
0.55 %
- 14. Storebrand Emerging Markets Plus A SEK
Sweden
0.21 %
- 15. Öhman Emerging Markets A
Sweden
0.21 %

The list of fund holdings was last updated on April 17, 2025.